3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Carboplatin
171
Paclitaxel
129
Radiotherapy
119
Cisplatin
109
Docetaxel
93
Gemcitabine
81
Erlotinib Hydrochloride
80
Pemetrexed
78
Bevacizumab
56
Etoposide
41
pembrolizumab
36
Gefitinib
32
Vinorelbine
31
Topotecan
30
Surveys and Questionnaires
29
Irinotecan
28
Radiosurgery
21
Nivolumab
20
Drug Therapy
20
Magnetic Resonance Spectroscopy
18
Cetuximab
18
durvalumab
17
Early Intervention, Educational
17
Blood Specimen Collection
17
Surgical Procedures, Operative
16
Cyclophosphamide
16
Celecoxib
15
Ipilimumab
14
Immunohistochemistry
14
Filgrastim
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lung Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled